One-year safety and tolerability of tezepelumab in Japanese patients with severe uncontrolled asthma: results of the NOZOMI study

Masaharu Shinkaia Division of Internal Medicine, Tokyo Shinagawa Hospital, Tokyo, JapanCorrespondence[email protected]

, MD, PhD,

Motohiro Ebisawab Clinical Research Center for Allergy and Rheumatology, NHO Sagamihara National Hospital, Sagamihara, Japan

, MD, PhD,

Yasushi Fukushimac Fukuwa Clinic, Tokyo, Japan

, MD, PhD,

Satomi Takeuchid Nihonbashi Medical and Allergy Clinic, Tokyo, Japan

, MD,

Hiroshi Okadae BioPharmaceuticals TA, R&D, AstraZeneca K.K., Osaka, Japan

, MD,

Tatsuro Tokiyof BioPharmaceuticals TA, R&D, AstraZeneca K.K., Tokyo, Japan

, MS,

Nobuya Hayashig Science and Data Analytics Division, R&D, AstraZeneca K.K., Osaka, Japan

, MS,

Mami Takikawah Development Operation Biopharma Clinical Operation, R&D, AstraZeneca K.K., Osaka, Japan

, MS,

Gene Colicei Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA

, MD &

Gun Almqvistj Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

Your download is now in progress and you may close this window